490 related articles for article (PubMed ID: 24916181)
1. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
2. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
3. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
Gayle SS; Castellino RC; Buss MC; Nahta R
Curr Med Chem; 2013; 20(19):2486-99. PubMed ID: 23531216
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
8. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Gayle SS; Arnold SL; O'Regan RM; Nahta R
Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
[TBL] [Abstract][Full Text] [Related]
9. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
Morse MA; Wei J; Hartman Z; Xia W; Ren XR; Lei G; Barry WT; Osada T; Hobeika AC; Peplinski S; Jiang H; Devi GR; Chen W; Spector N; Amalfitano A; Lyerly HK; Clay TM
Int J Cancer; 2010 Jun; 126(12):2893-903. PubMed ID: 19856307
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
11. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB; Garrett JT; Estrada MV; Moore PD; Ericsson PG; Koch JP; Langley E; Singh S; Kim PS; Frampton GM; Sanford E; Owens P; Becker J; Groseclose MR; Castellino S; Joensuu H; Huober J; Brase JC; Majjaj S; Brohée S; Venet D; Brown D; Baselga J; Piccart M; Sotiriou C; Arteaga CL
Clin Cancer Res; 2017 Aug; 23(15):4323-4334. PubMed ID: 28381415
[No Abstract] [Full Text] [Related]
12. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
13. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
14. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
15. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
16. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Gril B; Palmieri D; Bronder JL; Herring JM; Vega-Valle E; Feigenbaum L; Liewehr DJ; Steinberg SM; Merino MJ; Rubin SD; Steeg PS
J Natl Cancer Inst; 2008 Aug; 100(15):1092-103. PubMed ID: 18664652
[TBL] [Abstract][Full Text] [Related]
17. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
18. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
[TBL] [Abstract][Full Text] [Related]
19. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Schech AJ; Shah P; Yu S; Sabnis GJ; Goloubeva O; Rosenblatt P; Kazi A; Chumsri S; Brodie A
Breast Cancer Res Treat; 2015 Aug; 152(3):499-508. PubMed ID: 26133921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
